Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas
- PDF / 618,352 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 101 Downloads / 203 Views
ORIGINAL ARTICLE
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas Joon Young Hur 1,2 & Yeon Jeong Kim 3 & Sang Eun Yoon 1 & Dae-Soon Son 4 & Woong-Yang Park 3,5 & Seok Jin Kim 1 & Donghyun Park 3,6 & Won Seog Kim 1 Received: 11 December 2019 / Accepted: 19 March 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Cell-free DNA (cfDNA) can be released from tumor cells during proliferation and apoptosis; thus, a fraction of the cfDNA in patients with cancer is tumor-derived. However, the prognostic value of cfDNA in aggressive non-Hodgkin lymphoma (NHL) has not been determined. Between March 2017 and April 2019, plasma cfDNA was obtained from 158 patients with aggressive NHL who were registered in a prospective Samsung Medical Center lymphoma cohort (diffuse large B cell lymphoma (DLBCL), n = 51; T cell lymphoma (TCL), n = 51; NK/T cell lymphoma (NKTCL), n = 56). The concentration of cfDNA was estimated in longitudinal samples collected from patients with NHL before and during various chemotherapy regimens. In pretreatment samples, the median cfDNA concentration of all patients with aggressive lymphoma was 13.7 ng/dl (range 1.7–1792), which was significantly higher than that of healthy volunteers (median 7.4 ng, range 3.7–14.4, p < 0.001), and advanced stages showed a higher cfDNA level than earlier stages. Multivariate analysis identified high cfDNA as an independent factor for event-free survival that predicted poor prognosis in DLBCL (hazard ratio [HR] = 5.33, 95% confidence interval [CI] = 1.72–16.52, p = 0.003) and TCL (HR = 2.82, 95% CI = 1.10–7.20, p = 0.030). NKTCL patients with a high level of cfDNA had worse overall survival (HR = 4.71, 95% CI = 1.09–20.35, p = 0.037) compared with those with a low level of cfDNA. In this study, our results suggest the usefulness of pretreatment cfDNA as a prognostic marker for patients with DLBCL, TCL, and NKTCL. Keywords Cell-free DNA . Diffuse large B cell lymphoma . Aggressive T cell lymphoma . NK/T cell lymphoma
Introduction The presence of cell-free DNA (cfDNA) in blood plasma was discovered in 1948 by Mandel and Metais [1]. cfDNA originates from dying cells in various normal tissues and tumor lesions and appears as short fragments of DNA in plasma
and other body fluids [2]. Plasma cfDNA is released into the bloodstream through apoptosis or necrosis, and the level of cfDNA can increase under conditions of tissue stress, including exercise, inflammation, surgery, or tissue injury [3]. In 1977, it was demonstrated that in at least half of cancer patients, blood levels of cfDNA were significantly higher than in
Joon Young Hur and Yeon Jeong Kim contributed equally to this work. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00277-020-04008-3) contains supplementary material, which is available to authorized users. * Donghyun Park [email protected]
3
Samsung Genome Institute Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 063
Data Loading...
